Atea Pharmaceuticals, Inc.
AVIR· Nasdaq
Released Aug 8, 2023, after the close
10-Q filed Aug 8, 2023, 39 days after period end · 0000950170-23-039920
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | — | — | $60.39M | — |
| Net Income | -$28.18M | -$31.34M | $1.54M | -$9.99M |
| EPS Diluted |
Atea Pharmaceuticals, Inc. · CIK 1593899 · Engraved from SEC EDGAR
| -$0.34 |
| -$0.38 |
| $0.02 |
| -$0.99 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.